Skip to content
Open access

Computational drug repurposing identifies flavoxate as a novel NLRP3 inflammasome inhibitor for Alzheimer’s disease therapy

Jul 2026 · In Silico Pharmacology · Vol 14 · 0 citations · 27 references
Medicine

TL;DR

By repurposing Flavoxate, this work proposes a clinically translatable strategy to mitigate NLRP3-mediated neuroinflammation in AD, offering a potential disease modifying therapy with an established safety profile and underscores the significance of computational approaches in bridging the gap between preclinical discovery and therapeutic application for neurodegenerative diseases.

Read PDF

Similar papers

Aug 2026

Dual-site TAS2R14 binding by (-)-epicatechin gallate: A computational framework for neuroprotective drug repurposing.

Bitter taste receptors, particularly TAS2R14, are widely expressed in extraoral tissues, including the central nervous system, where they have been implicated in neuroinflammatory and neurodegenerative processes. Although numerous pharmacological and natural compounds have demonstrated therapeutic potential against neu...

Armin Sultana, Raju Das, Joohan Woo · 0 citations
Open access Sep 2026

Rational discovery of peptide inhibitors targeting Keap1: a focus on neurodegenerative diseases

The Kelch-like ECH-associated protein 1 (Keap1)/Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is a promising therapeutic target for neurodegenerative diseases (NDDs). Nrf2 activation mitigates key pathogenic mechanisms in NDDs by enhancing antioxidant defenses, suppressing neuroinflammation, improving...

Nandhini Senthilkumar, Shanthi Veerappapillai · 0 citations
Open access Aug 2026

Computational Repurposing of Janus Kinase Inhibitors as Potential Therapeutic Candidates for Alzheimer’s Disease

Background and Objectives: Alzheimer’s disease (AD) is the most common neurodegenerative disorder, and current therapies provide only limited symptomatic relief without effectively slowing its progression. Increasing evidence suggests that aberrant activation of the Janus kinase/signal transducer and activator of trans...

L. T. Nguyen, Mai Thi Nguyen, T. Nguyen · 0 citations
Open access Aug 2026

Integrated In Silico Discovery of Thymoquinone Analogs Targeting the Keap1–Nrf2 Pathway for Amyotrophic Lateral Sclerosis Therapy

This study identifies structurally tractable TQ analogs with improved predicted potency and establishes a robust computational framework for neuroprotective discovery as redox‐modulating agents in ALS.

Jabir C Nalicho, P. Mabeyo, Andrew S. Paluch et al. · 0 citations
Open access 2026

Discovery of Natural Alkaloid Inhibitors of NLRP3 Inflammasome: A Computational Approach Leveraging Brazilian Biodiversity

The NLRP3 inflammasome (NLR family pyrin domain-containing 3) plays a central role in the pathogenesis of several chronic inflammatory diseases, including rheumatoid arthritis, type 2 diabetes mellitus, and Alzheimer disease. However, currently available inhibitors, such as MCC950, present important limitations related...

Nalberth B. Farias, J. D. da Rocha, R. D. de Barros et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.